Inclisiran: a novel drug for the treatment of dyslipidemia.
作者信息
Nadeem Abdullah, Tariq Rabeea, Basaria Areeba
机构信息
Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan.
出版信息
Ann Med Surg (Lond). 2023 Jan 12;85(1):59-60. doi: 10.1097/MS9.0000000000000089. eCollection 2023 Jan.
Abstract
摘要
相似文献
1
Inclisiran: a novel drug for the treatment of dyslipidemia.英克西兰：一种治疗血脂异常的新型药物。
Ann Med Surg (Lond). 2023 Jan 12;85(1):59-60. doi: 10.1097/MS9.0000000000000089. eCollection 2023 Jan.
2
Inclisiran: a small interfering RNA strategy targeting PCSK9 to treat hypercholesterolemia.依洛尤单抗：一种靶向 PCSK9 的小干扰 RNA 策略，用于治疗高胆固醇血症。
Expert Opin Drug Saf. 2022 Jan;21(1):9-20. doi: 10.1080/14740338.2022.1988568. Epub 2021 Oct 14.
3
Inclisiran for the treatment of dyslipidemia.英克西兰用于治疗血脂异常。
Expert Opin Investig Drugs. 2018 Mar;27(3):287-294. doi: 10.1080/13543784.2018.1442435. Epub 2018 Feb 22.
4
Small interfering ribonucleic acid for cholesterol lowering - Inclisiran: Inclisiran for cholesterol lowering.用于降胆固醇的小干扰核糖核酸 - 依洛西仑：用于降胆固醇的依洛西仑。
J Clin Lipidol. 2022 Sep-Oct;16(5):574-582. doi: 10.1016/j.jacl.2022.06.009. Epub 2022 Jun 28.
5
Inclisiran in dyslipidemia.依洛尤单抗在血脂异常中的应用。
Drugs Today (Barc). 2021 May;57(5):311-319. doi: 10.1358/dot.2021.57.5.3277083.
6
Corrigendum: Novel Therapeutic Strategies for Dyslipidemia: First Report of Inclisiran Therapy in a Kidney Transplanted Patient.勘误：血脂异常的新型治疗策略：inclisiran治疗肾移植患者的首例报告。
Transpl Int. 2023 Mar 23;36:11313. doi: 10.3389/ti.2023.11313. eCollection 2023.
7
Inclisiran Lowers LDL-C and PCSK9 Irrespective of Diabetes Status: The ORION-1 Randomized Clinical Trial.依洛尤单抗降低 LDL-C 和 PCSK9 水平，与糖尿病状态无关：ORION-1 随机临床试验。
Diabetes Care. 2019 Jan;42(1):173-176. doi: 10.2337/dc18-1491. Epub 2018 Nov 28.
8
Effect of inclisiran, the small-interfering RNA against proprotein convertase subtilisin/kexin type 9, on platelets, immune cells, and immunological biomarkers: a pre-specified analysis from ORION-1.针对前蛋白转化酶枯草杆菌蛋白酶/ kexin 9型的小干扰RNA英克西兰对血小板、免疫细胞和免疫生物标志物的影响：来自ORION-1的预先指定分析。
Cardiovasc Res. 2021 Jan 1;117(1):284-291. doi: 10.1093/cvr/cvaa077.
9
[Inclisiran - a new era in lipid-lowering therapy].[英克西兰 - 降脂治疗的新时代]
Kardiologiia. 2022 Jun 30;62(6):57-62. doi: 10.18087/cardio.2022.6.n2115.
10
Inclisiran: A Novel Agent for Lowering Apolipoprotein B-containing Lipoproteins.依洛尤单抗：降低载脂蛋白 B 脂蛋白的新型药物。
J Cardiovasc Pharmacol. 2021 Aug 1;78(2):e157-e174. doi: 10.1097/FJC.0000000000001053.
本文引用的文献
1
Current Options and Future Perspectives in the Treatment of Dyslipidemia.血脂异常治疗的当前选择与未来展望
J Clin Med. 2022 Aug 12;11(16):4716. doi: 10.3390/jcm11164716.
2
Inclisiran-Silencing the Cholesterol, Speaking up the Prognosis.英克西兰——沉默胆固醇，改善预后。
J Clin Med. 2021 Jun 2;10(11):2467. doi: 10.3390/jcm10112467.
3
NDSP 05: Prevalence and pattern of dyslipidemia in urban and rural areas of Pakistan; a sub analysis from second National Diabetes Survey of Pakistan (NDSP) 2016-2017.NDSP 05：巴基斯坦城乡地区血脂异常的患病率及模式；来自2016 - 2017年巴基斯坦第二次全国糖尿病调查（NDSP）的子分析
J Diabetes Metab Disord. 2020 Oct 3;19(2):1215-1225. doi: 10.1007/s40200-020-00631-z. eCollection 2020 Dec.
4
Dyslipidemia and cardiovascular disease risk among the MASHAD study population.马什哈德研究人群的血脂异常与心血管疾病风险。
Lipids Health Dis. 2020 Mar 16;19(1):42. doi: 10.1186/s12944-020-01204-y.
5
Small Interfering RNA Therapeutic Inclisiran: A New Approach to Targeting PCSK9.小干扰 RNA 治疗性inclisiran：靶向 PCSK9 的新方法。
BioDrugs. 2020 Feb;34(1):1-9. doi: 10.1007/s40259-019-00399-6.
6
Expert opinion on the applicability of dyslipidemia guidelines in Asia and the Middle East.关于血脂异常指南在亚洲和中东地区适用性的专家意见。
Int J Gen Med. 2018 Jul 18;11:313-322. doi: 10.2147/IJGM.S160555. eCollection 2018.
7
A Highly Durable RNAi Therapeutic Inhibitor of PCSK9.一种高度耐用的PCSK9的RNAi治疗抑制剂。
N Engl J Med. 2017 Jan 5;376(1):41-51. doi: 10.1056/NEJMoa1609243. Epub 2016 Nov 13.
8
Statin treatment, new-onset diabetes, and other adverse effects: a systematic review.他汀类药物治疗、新发糖尿病及其他不良反应：系统评价。
Curr Cardiol Rep. 2014 Mar;16(3):461. doi: 10.1007/s11886-013-0461-4.
9
Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial.在健康志愿者中，一种 RNA 干扰药物对前蛋白转化酶枯草溶菌素/柯萨奇蛋白酶 9（PCSK9）合成和血清 LDL 胆固醇浓度的影响：一项随机、单盲、安慰剂对照、1 期临床试验。
Lancet. 2014 Jan 4;383(9911):60-68. doi: 10.1016/S0140-6736(13)61914-5. Epub 2013 Oct 3.
10
Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.针对枯草溶菌素转化酶 9 治疗血脂异常和动脉粥样硬化。
J Am Coll Cardiol. 2013 Oct 15;62(16):1401-8. doi: 10.1016/j.jacc.2013.07.056. Epub 2013 Aug 21.
Zotero 插件